Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 921-926

  Beck, H P ^a   Felger, I ^b   Huber, W ^b   Steiger, S ^b   Smith, T ^b   Weiss, N ^b   Alonso, P ^b   Tanner, M ^b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALARIA; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; TANZANIA;

EID: 0030901176     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513991     Document Type: Article

References (30)

1. Tanner M, Teuscher T, Alonso PL. SPf66 - the first malaria vaccine. Parasitol Today 1995;11:10-3.
2. Valero MV, Amador LR, Galindo C, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993;341:705-10.
3. Noya GO, Berti YG, deNoya BA, et al. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 1994;170:396-402.
4. Sempertegui F, Estrella B, Moscoso J, et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 1994;12:337-42.
5. Alonso PL, Smith T, Armstrong-Schellenberg JRM, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994;344:1175-81.
6. D'Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995;346:462-7.
7. Nosten F, Luxemburger C, Kyle DE, et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in north-western Thailand. Lancet 1996;348:701-7.
8. Smythe JA, Coppel RL, Brown GV, Ramasamy R, Kemp DJ, Anders RF. Identification of two integral membrane proteins of Plasmodium falciparum. Proc Natl Acad Sci USA 1988;85:5195-9.
9. Conway DJ, Greenwood BM, McBride JS. The epidemiology of multiple-clone Plasmodium falciparum infections in Gambian patients. Parasitology 1991;103:1-6.
10. Felger I, Tavul L, Kabintik S, et al. Plasmodium falciparum: extensive polymorphism in merozoite surface antigen 2 alleles in an area with endemic malaria in Papua New Guinea. Exp Parasitol 1994;79:106-16.
11. Babiker HA, Charlwood JD, Smith T, Walliker D. Gene flow and cross-mating in Plasmodium falciparum in households in a Tanzanian village. Parasitology 1995;111:433-42.
12. Contamin H, Fandeur T, Bonnefoy S, Skouri F, Ntoumi F, Mercereau-Puijalon O. PCR typing of field isolates of Plasmodium falciparum. J Clin Microbiol 1995;33:944-51.
13. Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape JF, Mercereau-Puijalon O. Age-dependent carriage of multiple Plasmodium falciparum merozoite surface antigen-2 alleles in asymptomatic malaria infections. Am J Trop Med Hyg 1995;52:81-8.
14. Babiker HA, Ranford-Cartwright LC, Currie D, et al. Random mating in a natural population of the malaria parasite Plasmodium falciparum. Parasitology 1994;109:413-21.
15. Engelbrecht F, Felger I, Genton B, Alpers M, Beck HP. Plasmodium falciparum: malaria morbidity is associated with specific merozoite surface antigen 2 genotypes. Exp Parasitol 1995;81:90-6.
16. Paul REL, Packer MJ, Walmsley M, et al. Mating patterns in malaria parasite populations of Papua New Guinea. Science 1995;269:1709-11.
17. Alonso PL, Tanner M, Smith T, et al. A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design. Vaccine 1994;12:181-6.
18. Alonzo (Alonso) PL, Smith T, Armstrong-Schellenberg JRM, et al. Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Med Trop 1995;55:41S-6S.
19. Alonso PL, Smith T, Armstrong-Schellenberg J, et al. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J Infect Dis 1996;174:367-72.
20. Foley M, Ranford-Cartwright LC, Babiker HA. Rapid and simple method for isolating malaria DNA from fingerprick samples of blood. Mol Biochem Parasitol 1992;53:241-4.
21. Felger I, Tavul L, Beck HP. Plasmodium falciparum: a rapid technique for genotyping the merozoite surface protein 2. Exp Parasitol 1993;77:372-5.
22. Marshall VM, Coppel RL, Martin RK, Oduola AMJ, Anders RF, Kemp DJ. A Plasmodium falciparum MSA-2 gene apparently generated by intragenic recombination between the two allelic families. Mol Biochem Parasitol 1991;45:349-52.
23. Smith T, Charlwood JD, Kihonda J, et al. Absence of seasonal variation in malaria parasitemia in an area of intense transmission. Acta Trop 1993;54:55-72.
24. Patarroyo ME, Amador R, Clavijo P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988;332:158-61.
25. Patarroyo ME, Romero P, Torres ML, et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987;328:629-32.
26. Kwiatkowski D. Malaria toxins and the regulation of parasite density. Parasitol Today 1995;11:206-12.
27. Kwiatkowski D. Malaria: becoming more specific about non-specific immunity. Curr Opinion Immunol 1992;4:425-31.
28. Gupta S, Hill AVS, Kwiatkowski D, Greenwood AM, Greenwood BM, Day KP. Parasite virulence and disease patterns in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1994;91:3715-9.
29. Marsh K. Malaria - a neglected disease? Parasitology 1992;104:53-69.
30. Sergent E, Donatien A, Parrot FC, Plantureaux E, Rougebief H. Etudes expérimentales sur les piroplasmoses bovines d'Algerie. Ann Inst Pasteur 1924;38:273-9.